Cytomegalovirus (CMV) Infection Therapeutic Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)
Cytomegalovirus (CMV) Infection Therapeutic Market is segmented By Drug Type (Valgnciclovir, Ganciclovir, Cidofovir, Foscarnet), By Application (Organ Transplantation, Stem cell Transplantation, Congenital CMV Infection), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD million) for the above-mentioned.
Cytomegalovirus (CMV) Infection Therapeutic Market Size
Market Size in USD
CAGR7.10%
| Study Period | 2024 - 2031 |
| Base Year of Estimation | 2023 |
| CAGR | 7.10% |
| Market Concentration | Medium |
| Major Players | Moderna, Trellis Bioscience, SpyBiotech, Vical, Atara Biotherapeutics |
please let us know !
Cytomegalovirus (CMV) Infection Therapeutic Market Analysis
The Global Cytomegalovirus (CMV) Infection Therapeutic Market is estimated to be valued at USD 231.4 Mn in 2024 and is expected to reach USD 370.2 Mn by 2031, growing at a compound annual growth rate (CAGR) of 7.10% from 2024 to 2031. The market has been mainly driven by the rising incidence of CMV infections among infants and AIDS patients as well as availability of late-stage pipeline drugs which are likely to enter the market in the coming years.
The market trend has shown steady and gradual growth over the past few years. Recent research and partnerships between companies have worked to improve diagnostic techniques and therapeutic development for CMV infection. Additionally, rising awareness regarding hygiene practices and prevention of infection has positively impacted the market size. Further innovations to provide broader treatment options are expected to continue driving the market during the forecast period.